{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:26:23Z","timestamp":1790303183339,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T00:00:00Z","timestamp":1539907200000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"VSV-EBOVAC","award":["115842"],"award-info":[{"award-number":["115842"]}]},{"name":"VSV-EBOPLUS","award":["116068"],"award-info":[{"award-number":["116068"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.smim.2018.07.003","type":"journal-article","created":{"date-parts":[[2018,7,21]],"date-time":"2018-07-21T18:08:54Z","timestamp":1532196534000},"page":"65-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Correlates of vaccine-induced protective immunity against Ebola virus disease"],"prefix":"10.1016","volume":"39","author":[{"given":"Donata","family":"Medaglini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire-Anne","family":"Siegrist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2018.07.003_bib0005","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s10096-015-2457-z","article-title":"Clinical characteristics of 154 patients suspected of having Ebola virus disease in the Ebola holding center of Jui Government Hospital in Sierra Leone during the 2014 Ebola outbreak","volume":"34","author":"Yan","year":"2015","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.smim.2018.07.003_bib0010","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2174\/156652405774962344","article-title":"Ebola and Marburg viruses: pathogenesis and development of countermeasures","volume":"5","author":"Hensley","year":"2005","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.smim.2018.07.003_bib0015","doi-asserted-by":"crossref","first-page":"9733","DOI":"10.1128\/JVI.77.18.9733-9737.2003","article-title":"Ebola virus pathogenesis: implications for vaccines and therapies","volume":"77","author":"Sullivan","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2018.07.003_bib0020","series-title":"Ebola situation reports: archive, WHO. (n.d.)","author":"WHO","year":"2018"},{"key":"10.1016\/j.smim.2018.07.003_bib0025","first-page":"548","article-title":"Centers for Disease Control and prevention (CDC), Ebola viral disease outbreak\u2013West Africa, 2014","volume":"63","author":"Dixon","year":"2014","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.smim.2018.07.003_bib0030","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2015.19","article-title":"A review of epidemiological parameters from Ebola outbreaks to inform early public health decision-making","volume":"2","author":"Van Kerkhove","year":"2015","journal-title":"Sci. Data"},{"key":"10.1016\/j.smim.2018.07.003_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)31387-4","article-title":"Outbreak of Ebola virus disease in the Democratic Republic of the Congo, April\u2013May, 2018: an epidemiological study","author":"Barry","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.smim.2018.07.003_bib0040","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1128\/JVI.78.10.5458-5465.2004","article-title":"Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses","volume":"78","author":"Garbutt","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2018.07.003_bib0045","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/78654","article-title":"Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury","volume":"6","author":"Yang","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2018.07.003_bib0050","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"issue":"10068","key":"10.1016\/j.smim.2018.07.003_bib0055","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.smim.2018.07.003_bib0060","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1056\/NEJMp1806978","article-title":"Keeping your cool - doing Ebola research during an emergency","volume":"378","author":"Haug","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2018.07.003_bib0065","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cis238","article-title":"Nomenclature for immune correlates of protection after vaccination","volume":"54","author":"Plotkin","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.smim.2018.07.003_bib0070","series-title":"3 - Correlates of Protection, in: Plotkin\u2019s Vaccines","first-page":"35","author":"Plotkin","year":"2018"},{"key":"10.1016\/j.smim.2018.07.003_bib0075","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/INF.0b013e3181c67f04","article-title":"Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom","volume":"29","author":"Goldblatt","year":"2010","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.smim.2018.07.003_bib0080","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1086\/422531","article-title":"Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media","volume":"190","author":"Jokinen","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.smim.2018.07.003_bib0085","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1128\/CVI.05313-11","article-title":"Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concentrations determined by enzyme-linked immunosorbent assay with 22F adsorption","volume":"18","author":"Schuerman","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.smim.2018.07.003_bib0090","doi-asserted-by":"crossref","first-page":"e02260","DOI":"10.1128\/mBio.02260-15","article-title":"Reduction of streptococcus pneumoniae colonization and dissemination by a nonopsonic capsular Polysaccharide antibody","volume":"7","author":"Doyle","year":"2016","journal-title":"MBio"},{"key":"10.1016\/j.smim.2018.07.003_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/163.1.1","article-title":"Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines","volume":"163","author":"Onorato","year":"1991","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.smim.2018.07.003_bib0100","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrmicro2129","article-title":"Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule","volume":"7","author":"Sullivan","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.smim.2018.07.003_bib0105","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature17949","article-title":"Unique human immune signature of Ebola virus disease in Guinea","volume":"533","author":"Ruibal","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.smim.2018.07.003_bib0110","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13059-016-1137-3","article-title":"Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus","volume":"18","author":"Liu","year":"2017","journal-title":"Genome Biol."},{"key":"10.1016\/j.smim.2018.07.003_bib0115","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004582","article-title":"Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates","volume":"4","author":"Wong","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2018.07.003_bib0120","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiy316","article-title":"Role of antibodies in protection against Ebola virus in nonhuman primates immunized with three vaccine platforms","author":"Warfield","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.smim.2018.07.003_bib0125","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nm.2447","article-title":"CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates","volume":"17","author":"Sullivan","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2018.07.003_bib0130","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.coviro.2017.03.008","article-title":"Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine","volume":"23","author":"Medaglini","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.smim.2018.07.003_bib0135","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2018.07.003_bib0140","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"rVSV\u0394G-ZEBOV-GP study group, a recombinant vesicular stomatitis virus Ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2018.07.003_bib0145","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"VSV-Ebola consortium, the effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.smim.2018.07.003_bib0150","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.smim.2018.07.003_bib0155","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1093\/infdis\/jix189","article-title":"V920-012 study team, six-month safety data of recombinant vesicular stomatitis virus-zaire Ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults","volume":"215","author":"Halperin","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.smim.2018.07.003_bib0160","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against Ebola virus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2018.07.003_bib0165","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2018.07.003_bib0170","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1410863","article-title":"VRC 207 study team, chimpanzee adenovirus vector Ebola vaccine","volume":"376","author":"Ledgerwood","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2018.07.003_bib0175","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","article-title":"Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia","volume":"377","author":"Kennedy","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2018.07.003_bib0180","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"389","author":"Zhu","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.smim.2018.07.003_bib0185","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.smim.2018.07.003_bib0190","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1128\/JVI.02407-10","article-title":"Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge","volume":"85","author":"Geisbert","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2018.07.003_bib0195","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2018.07.003_bib0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000225","article-title":"Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates","volume":"4","author":"Geisbert","year":"2008","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.smim.2018.07.003_bib0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001567","article-title":"Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates","volume":"6","author":"Mire","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.smim.2018.07.003_bib0210","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.aab3920","article-title":"Ebola VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014\/15 Ebola virus outbreak strain","volume":"349","author":"Marzi","year":"2015","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.smim.2018.07.003_bib0215","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1093\/infdis\/jiw218","article-title":"Efficacy of vesicular stomatitis virus-Ebola virus postexposure treatment in rhesus macaques infected with Ebola virus makona","volume":"214","author":"Marzi","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.smim.2018.07.003_bib0220","doi-asserted-by":"crossref","first-page":"e2600","DOI":"10.1371\/journal.pntd.0002600","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo Ebola virus","volume":"7","author":"Mire","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"Suppl. (3)","key":"10.1016\/j.smim.2018.07.003_bib0225","doi-asserted-by":"crossref","first-page":"S1082","DOI":"10.1093\/infdis\/jir350","article-title":"Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo Ebola virus","volume":"204","author":"Falzarano","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.smim.2018.07.003_bib0230","first-page":"1647","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe \u2013 preliminary report","volume":"347","author":"Agnandji","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2018.07.003_bib0235","article-title":"rVSV\u0394G-ZEBOV-GP study group, a recombinant vesicular stomatitis virus Ebola vaccine - preliminary report","author":"Regules","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2018.07.003_bib0240","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"Articles the effect of dose on the safety and immunogenicity of the VSV ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.smim.2018.07.003_bib0245","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S1473-3099(17)30313-4","article-title":"V920-004 study team, safety and immunogenicity of the rVSV\u0394G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study","volume":"17","author":"Heppner","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.smim.2018.07.003_bib0250","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1016\/j.vaccine.2017.05.097","article-title":"Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic","volume":"35","author":"Coller","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.07.003_bib0255","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"rVSV\u0394G-ZEBOV-GP study group, a recombinant vesicular stomatitis virus ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2018.07.003_bib0260","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S1473-3099(17)30541-8","article-title":"Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report","volume":"17","author":"Gsell","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.smim.2018.07.003_bib0265","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/nm.4201","article-title":"Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies","volume":"22","author":"Khurana","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2018.07.003_bib0270","series-title":"Circulating Follicular T Helper Cells and Cytokine Profile in Humans Following Vaccination With the rVSV-ZEBOV Ebola Vaccine","first-page":"1","author":"Farooq","year":"2016"},{"key":"10.1016\/j.smim.2018.07.003_bib0275","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.celrep.2017.08.023","article-title":"Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the Ebola vaccine rVSV-ZEBOV","volume":"20","author":"Rechtien","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.smim.2018.07.003_bib0280","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj1701","article-title":"A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa","volume":"9","author":"Huttner","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.smim.2018.07.003_bib0285","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1473-3099(18)30165-8","article-title":"Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study","volume":"18","author":"Huttner","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.smim.2018.07.003_bib0290","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/ni.2789","article-title":"Molecular signatures of antibody responses derived from a systems biology study of five human vaccines","volume":"15","author":"Li","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2018.07.003_bib0295","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1073\/pnas.1519690113","article-title":"Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood","volume":"113","author":"Nakaya","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.smim.2018.07.003_bib0300","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1073\/pnas.1621489114","article-title":"Systems analysis of protective immune responses to RTS,S malaria vaccination in humans","volume":"114","author":"Kazmin","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.smim.2018.07.003_bib0305","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans","volume":"10","author":"Querec","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2018.07.003_bib0310","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1128\/CVI.00733-14","article-title":"Next-generation sequencing reveals a controlled immune response to Zaire Ebola virus challenge in cynomolgus macaques immunized with vesicular stomatitis virus expressing Zaire Ebola virus glycoprotein (VSV\u0394G\/EBOVgp)","volume":"22","author":"Barrenas","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.smim.2018.07.003_bib0315","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41598-017-01032-8","article-title":"Transcriptomic analysis reveals a previously unknown role for CD8+ T-cells in rVSV-EBOV mediated protection","volume":"7","author":"Menicucci","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.smim.2018.07.003_bib0320","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad3106","article-title":"Ebola vaccine R&D: filling the knowledge gaps","volume":"7","author":"Medaglini","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2018.07.003_bib0325","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003826","article-title":"ADITEC: joining forces for next-generation vaccines","volume":"4","author":"Rappuoli","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2018.07.003_bib0330","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.vaccine.2017.11.069","article-title":"Innovation partnership for a roadmap on vaccines in Europe (IPROVE): a vision for the vaccines of tomorrow","volume":"36","author":"Medaglini","year":"2018","journal-title":"Vaccine"}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532318300253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532318300253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:13:06Z","timestamp":1760915586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532318300253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":66,"alternative-id":["S1044532318300253"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2018.07.003","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlates of vaccine-induced protective immunity against Ebola virus disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2018.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}